@JNCI_Now We defined the gene expression profiles distinguishing HPV+ OPSCCs that are prone to recur after TORS-based therapy. These the tumor-intrinsic and immune-related traits were tightly interrelated and generalizeable to nonsurgical cases as well. academic.oup.com/jnci/advanc…
Well written review by @imrtlee@xrtGenomics et al and an easy read for the non-rad onc, contextualizing differences between the two phase III trials comparing IMRT to IMPT for oropharyngeal cancer. ascopubs.org/doi/full/10.120…
So proud to be a Pennsylvanian with a Republican Senator like Dave McCormick. Thank you Senator McCormick for strongly supporting biomedical research and NIH.
washingtonpost.com/opinions/…
Highlighting our infographic with @AHNS on the significance of discordant HPV confirmatory testing in p16+ oropharyngeal cancer and current US guidelines for using it.
Presented by the AHNS Annual Basic & Translational Science Service. Prepared by @MollyEHeftNeal and @basulab1, this infographic explores HPV/p16 discordance in oropharyngeal cancer, its prognostic & therapeutic relevance, and implications for confirmatory HPV testing.
#AHNS
Question born in a clinic. 74 patients with HNSCC undergoing CTRT. Two blinded oncologists grading toxicities.
Now in Red Journal
Mucositis, ≥G2 κ: 0.23–0.41 | 91.9% vs 70.2%,
Assessor = hidden covariate in every tox endpoint
doi.org/rmn6@IJROBP@RadOncTMC
The final paper from Gough/Crittenden Lab @providence is out in J of Immunology.
Kaede tracking shows the tumor-draining lymph node refills irradiated tumors with T cells — support for lymphatic-sparing immunoradiotherapy in H&N cancer. academic.oup.com/jimmunol/ar…
Updated results from JCOG 1008 (bolus versus weekly cis for postoperative CRT in high-risk patients) are out.
Weekly cisplatin was clearly non-inferior and in fact numerically superior from both a disease- and safety- perspective. The clear winner.
It will be very interesting to see the final results from HN009 (definitive CRT), especially in an HPV-negative population that may be at higher risk for treatment-related toxicity.
ascopubs.org/doi/full/10.120…
Dr Gillison played a central role in elucidating the clinical and molecular epidemiology of HPV+ oropharyngeal cancer and made critical contributions to our understanding of HPV genome states in malignancy.
Mark A. Varvares, MD, FACS, passed away on May 20, 2026 surrounded by his family leaving behind a legacy defined by the countless lives he has touched
Viewing and funeral service will be Saturday, May 30th, St Nicholas Greek Orthodox Church in St Louis, MO
buff.ly/iORf2w8
Sharing the results of ReACT 1.0 in @NatureComms -- the first study to use HPV ctDNA to guide CRT de-escalation in higher risk HPV+ OPC. ctDNA metrics may improve risk stratification. Grateful to our coauthors. @Naveris_inc @DanaFarberNews@jdschoenfeld1nature.com/articles/s41467-0…